Policy Statement

I. Targeted genetic testing for a known familial variant in the presenilin (PSEN1, PSEN2) genes or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease (AD) may be considered medically necessary in an asymptomatic or minimally symptomatic individual to determine future risk of disease when the individual has a close relative (i.e., first- or second-degree relative) with a known familial variant associated with autosomal dominant early-onset Alzheimer disease (see Policy Guidelines).

II. Genetic testing for variants in presenilin (PSEN1, PSEN2) genes or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease may be considered medically necessary in an asymptomatic or minimally symptomatic individual to determine future risk of disease when the individual has a family history of dementia consistent with autosomal dominant Alzheimer disease for whom the genetic status of the affected family members is unavailable.

III. Genetic testing for the risk assessment of Alzheimer disease in asymptomatic individuals is considered investigational in all other situations. Genetic testing includes but is not limited to, testing for the apolipoprotein E (APOE) epsilon 4 (ε4) allele or triggering receptor expressed on myeloid cells 2 (TREM2).

IV. Genetic testing to guide initiation or management of a U.S. Food and Drug Administration-approved amyloid-beta targeting therapy (e.g., aducanumab) is considered investigational. Genetic testing includes but is not limited to, testing for the APOE epsilon 4 allele.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Testing Strategy
The 2011 guidelines from the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors recommended that genetic testing for early-onset, autosomal dominant Alzheimer disease (AD) should only occur in the context of genetic counseling with support by someone expert in the area. In asymptomatic patients, a testing protocol based on the 1994 International Huntington Association and World Federation of Neurology Research Group on Huntington’s Chorea guidelines has been recommended. Consultation of the Alzheimer Disease & Frontotemporal Dementia Mutation Database has also been recommended before disclosure of genetic test results.

A family history of autosomal dominant Alzheimer disease (AD) is suggested by 3 affected members in 2 generations. Testing for genes associated with early-onset autosomal dominant AD is appropriate for symptomatic individuals with early-onset Alzheimer disease in the setting of a family history of dementia, the setting of an unknown family history (e.g., adoption), or for guiding testing of unaffected family members making reproductive decisions. In individuals at risk of early-onset, autosomal dominant AD, ideally, an affected family member should be tested first to identify the familial variant. Additionally, targeted testing of the parents of a proband with early-onset autosomal dominant AD and a confirmed genetic variant to identify mode of transmission (germline versus de novo) may be considered appropriate in some families, such as families with unaffected
parents and no affected closely related family members. If no affected family member is available for testing and an asymptomatic individual remains interested in testing to inform reproductive decision making, then in-depth sequencing of the 3 genes (\textit{APP, PSEN1, PSEN2}) associated with autosomal dominant AD may be indicated.

\textbf{Genetics Nomenclature Update}
The \textit{Human Genome Variation Society (HGVS)} nomenclature is used to report information on variants found in deoxyribonucleic acid (DNA) and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (Table PG1). The Society’s nomenclature is recommended by the \textit{Human Variome Project}, the \textit{Human Genome Organization (HUGO)}, and by the \textit{Human Genome Variation Society itself}.

The American College of Medical Genetics and Genomics (ACMG) and the \textit{Association for Molecular Pathology (AMP)} standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the \textit{College of American Pathologists}. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

\textbf{Table PG1. Nomenclature to Report on Variants Found in DNA}

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associating variant</td>
<td>Disease-associating change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td></td>
<td>Change in the DNA sequence</td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associating variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
<td></td>
</tr>
</tbody>
</table>

\textbf{Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification}

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

\textbf{Genetic Counseling}
Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

\textbf{Coding}
The following CPT coding is used to report \textit{APOE, PSEN}, and \textit{APP} testing:

- \textbf{81401}: Molecular Pathology Procedure Level 2 (includes \textit{APOE [apolipoprotein E]} [e.g., hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease], common variants [e.g., *2, *3, *4])
- \textbf{81405}: Molecular Pathology Procedure Level 6 (includes \textit{PSEN1 [presenilin 1]} [e.g., Alzheimer disease], full gene sequence)}
• **81406**: Molecular Pathology Procedure Level 7 (includes: APP [amyloid beta (A4) precursor protein] [e.g., Alzheimer disease], full gene sequence and PSEN2 [presenilin 2 (Alzheimer disease 4)] [e.g., Alzheimer disease], full gene sequence)

There following is a HCPCS code specific to APOE ε4 allele testing:
• **S3852**: DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer's disease

There is a MAAA test that tracks memory functioning and predicts short and long-term risks for clinical worsening and developing Alzheimer’s disease. It matches patients with possible medications and may be repeated to monitor treatment response. It uses an algorithm reported as predictive risk score.
• **0289U**: Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score

### Description

Alzheimer disease (AD) is the most common cause of dementia in elderly patients. For late-onset AD, there is a component of risk that runs in families, suggesting the contribution of genetic factors. Early-onset AD is much less common but can occur in non-elderly individuals. Early-onset AD has a stronger component of family risk, with clustering in families, thus suggesting an inherited genetic disease-causing variant.

### Related Policies

• Evaluation of Biomarkers for Alzheimer Disease
• Selected Positron Emission Tomography Technologies for Evaluation of Alzheimer Disease

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing.

In November 2017, the 23andMe Personal Genome Service (PGS) Test with Genetic Health Risk Report for Late-onset Alzheimer Disease was granted a de novo classification by the U.S. Food and Drug Administration (class II with general and special controls, FDA product code: PTA). This is a direct-to-consumer test that has been evaluated by the FDA for accuracy, reliability, and consumer
comprehension. This test reports whether an individual has variants associated with late-onset AD by detecting the presence of the APOE ε4 (rs429353) gene variant.

In June 2021, aducanumab (Aduhelm; Biogen) was approved by the FDA for treatment of AD. This indication was approved under accelerated approval based on reduction in amyloid-beta plaques observed in patients treated with aducanumab. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

In July 2021, the FDA amended the approved label to emphasize the disease stages studied in the clinical trials. The amended label states, "Treatment with aducanumab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied."

The FDA, under the accelerated approval regulations (21 CFR 601.41), requires that Biogen conduct a randomized, controlled trial to evaluate the efficacy of aducanumab-avwa compared to an appropriate control for the treatment of AD. The trial should be of sufficient duration to observe changes on an acceptable endpoint in the patient population enrolled in the trial. The expected date of trial completion is August 2029 with final report submission to the FDA by February 2030.

Rationale

Background

Alzheimer Disease

Alzheimer disease (AD) is commonly associated with a family history; 40% of patients with AD have at least 1 other afflicted first-degree relative. Numerous genes have been associated with late-onset AD, while variants in chromosomes 1, 14, and 21 have been associated with early-onset familial AD.1

Genetic Variants

Individuals with early-onset familial AD (i.e., before age 65 years but as early as 30 years) form a small subset of AD patients. Alzheimer disease within families of these patients may show an autosomal dominant pattern of inheritance. Pathogenic variants in 3 genes have been identified in affected families: the amyloid-beta precursor protein (APP) gene, presenilin 1 (PSEN1) gene, and presenilin 2 (PSEN2) gene. APP and PSEN1 variants have 100% penetrance absent death from other causes, while PSEN2 has 95% penetrance. Variants within these genes have been associated with AD; variants in PSEN1 appear to be the most common. While only 3% to 5% of all patients with AD have early-onset disease, pathogenic variants have been identified in 70% or more of these patients. Identifiable genetic variants are, therefore, rare causes of AD.

Testing for the apolipoprotein E (APOE) epsilon 4 allele among patients with late-onset AD and for APP, PSEN1, or PSEN2 pathogenic variants in the rare patient with early-onset AD has been investigated as an aid in diagnosis of patients presenting with symptoms suggestive of AD, or as a technique for risk assessment in asymptomatic patients with a family history of AD. Pathogenic variants in PSEN1 and PSEN2 are specific for AD; APP variants are also found in cerebral hemorrhagic amyloidosis of the Dutch type, a disease in which dementia and brain amyloid plaques are uncommon.

The APOE lipoprotein is a carrier of cholesterol produced in the liver and brain glial cells. The APOE gene has 3 alleles—ε2, 3, and 4—with the ε3 allele being the most common. Individuals carry 2 APOE alleles. The presence of at least one, ε4 allele is associated with a 1.2- to 3-fold increased risk of AD, depending on the ethnic group. Among those homozygous for ε4 (≈2% of the population), the risk of AD is higher than for those heterozygous for ε4. Mean age of onset of AD is about age 68.
years for ε4 homozygotes, about 77 years for heterozygotes, and about 85 years for those with no ε4 alleles. About half of patients with sporadic AD carry a ε4 allele. However, not all patients with the allele develop AD. The ε4 allele represents a risk factor for AD rather than a disease-associated variant. In the absence of APOE testing, first-degree relatives of an individual with sporadic or familial AD are estimated to have a 2- to 4-fold greater risk of developing AD than the general population.4 There is evidence of possible interactions between ε4 alleles, other risk factors for AD (e.g., risk factors for cerebrovascular disease such as smoking, hypertension, hypercholesterolemia, diabetes),3 and a higher risk of developing AD. However, it is not clear that all risk factors have been taken into account in such studies, including the presence of variants in other genes that may increase the risk of AD.

Studies have also identified rs75932628-T, a rare functional substitution for R47H on the triggering receptor expressed on myeloid cells 2 (TREM2), as a heterozygous risk variant for late-onset AD.4,5 On chromosome 6p21.1, at position 47 (R47H), the T allele of rs75932628 encodes a histidine substitute for arginine in the gene that encodes TREM2.

TREM2 is highly expressed in the brain and is known to have a role in regulating inflammation and phagocytosis. TREM2 may serve a protective role in the brain by suppressing inflammation and clearing it of cell debris, amyloids, and toxic products. A decrease in the function of TREM2 would allow inflammation in the brain to increase and may be a factor in the development of AD. The effect size of the TREM2 variant confers a risk of AD that is similar to the APOE ε4 allele, although it occurs less frequently.

Diagnosis
The diagnosis of AD is divided into 3 categories: possible, probable, and definite AD.6 A diagnosis of definite AD requires postmortem confirmation of AD pathology, documenting the presence of extracellular amyloid-beta plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. As a result, a diagnosis of definite AD cannot be made during life, and the diagnosis of probable or possible AD is made on clinical grounds.7 Probable AD dementia is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. Criteria for diagnosis of probable AD have been developed by the National Institute on Aging and the Alzheimer’s Association.6 These criteria require evidence of a specific pattern of cognitive impairment, a typical clinical course, and exclusion of other potential etiologies, as follows:

- **Cognitive impairment**
  - Cognitive impairment established by history from the patient and a knowledgeable informant, plus objective assessment by bedside mental status examination or neuropsychological testing.
  - Cognitive impairment involving a minimum of 2 of the following domains:
    - Impaired ability to acquire and remember new information
    - Impaired reasoning and handling of complex tasks, poor judgment
    - Impaired visuospatial abilities
    - Impaired language functions
    - Changes in personality, behavior, or comportment.
  - Initial and most prominent cognitive deficits are 1 of the following:
    - Amnestic presentation
    - Nonamnestic presentations, either a language presentation with prominent word-finding deficits; a visuospatial presentation with visual cognitive defects; or a dysexecutive presentation with prominent impairment of reasoning, judgment, and/or problem-solving.
- **Clinical course**
  - Insidious onset
  - Clear-cut history of worsening over time
  - Interference with the ability to function at work or usual activities
  - Decline from previous level of functioning and performing.
Exclusion of other disorders:
  - Cognitive decline not explained by delirium or major psychiatric disorder;
  - No evidence of other active neurologic diseases, including substantial cerebrovascular disease or dementia with Lewy bodies;
  - Lack of prominent features of variant frontotemporal dementia or primary progressive aphasia;
  - No medication used with substantial effects on cognition.

A diagnosis of possible AD dementia is made when the patient meets most of the AD criteria but has an atypical course or an etiologically mixed presentation. This may consist of an atypical onset (e.g., sudden onset) or atypical progression. A diagnosis of possible AD is also made when there is another potentially causative systemic or neurologic disorder that is not thought to be the primary etiology of dementia.

Mild cognitive impairment is a precursor of AD in many instances. Mild cognitive impairment may be diagnosed when there is a change in cognition, but insufficient impairment for the diagnosis of dementia. Features of mild cognitive impairment are evidence of impairment in 1 or more cognitive domains and preservation of independence in functional abilities. In some patients, mild cognitive impairment may be a predementia phase of AD. Patients with mild cognitive impairment may undergo ancillary testing (e.g., neuroimaging, laboratory studies, neuropsychological assessment) to rule out vascular, traumatic, and medical causes of cognitive decline and to evaluate genetic factors.

Biomarker evidence has been integrated into the diagnostic criteria for probable and possible AD for use in research settings. Other diagnostic tests for AD include cerebrospinal fluid levels of tau protein or amyloid precursor protein, as well as positron emission tomography amyloid imaging. The cerebrospinal fluid tests are considered separately in Blue Shield of California Medical Policy: Evaluation of Biomarkers for Alzheimer Disease. Positron emission tomography amyloid imaging is considered in Blue Shield of California Medical Policy: Selected Positron Emission Tomography Technologies for Evaluation of Alzheimer Disease.

**Literature Review**

The review was informed by a TEC Assessment (1999). Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms are better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Genetic Testing for Late-Onset Alzheimer Disease**

**Clinical Context and Test Purpose**

The purpose of genetic testing in patients who are asymptomatic and at risk for developing late-onset Alzheimer disease (AD) is potentially to inform management decisions such as early treatment or behavioral changes. Asymptomatic patients at risk of late-onset AD are not generally treated with medical therapy but may choose to make behavioral changes associated with reduced risk of AD.

The question addressed in this evidence review is: Does genetic testing improve health outcomes in individuals who are asymptomatic and at risk for developing late-onset AD?

The following PICO was used to select literature to inform this review.
Populations
The relevant population of interest is adults who are asymptomatic and at risk for developing late-onset AD due to a family history of AD or dementia.

Interventions
The test being considered is genetic testing. It can be performed on a number of candidate genes, individually or collectively. Lists of genes associated with AD and testing laboratories in the U.S. are provided on the Genetic Testing Registry website of the National Center for Biotechnology Information.10.

Genetic testing for variants associated with late-onset AD is complex. Referral for genetic counseling is important for the explanation of the genetic disease, heritability, genetic risk, test performance, and possible outcomes.

Comparators
The following practice is currently being used: standard clinical management without genetic testing.

Outcomes
The general outcomes of interest are a change in disease status, health status measures, and quality of life. Specific outcomes in each of these categories are listed in Table 1.

The potential beneficial outcomes of primary interest would be change in disease status if changes in management or behavior in asymptomatic patients at risk of late-onset AD are initiated that prevent or slow the progression of cognitive decline. Improvement in health status measures is also important.

Potential harmful outcomes are those resulting from a true- or false-positive test result. Patients might suffer from psychological harm or anxiety after receiving positive test results.

Table 1. Outcomes of Interest for Individuals With Symptomatic Late-Onset Alzheimer Disease

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in disease status</td>
<td>Incidence or time to Alzheimer disease onset; changes in cognitive test scores</td>
</tr>
<tr>
<td>Health status measures</td>
<td>Activities of daily living or functional scales such as the 36-Item Short-Form Health Survey, Alzheimer Disease Cooperative Study Activities of Daily Living scale, or Disability Assessment for Dementia</td>
</tr>
<tr>
<td>Quality of life</td>
<td>EuroQoL EQ-5D; measures of anxiety or depression</td>
</tr>
</tbody>
</table>

Trials of genetic testing in this population have been sparse and generally included short-term outcomes of distress and anxiety measured within a year. Trials of prevention strategies in AD typically span many years to a decade to detect differences in conversion to AD in asymptomatic, at-risk individuals.

Study Selection Criteria
For the evaluation of clinical validity of genetic testing for AD, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard (describe the reference standard)
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Diagnostic tests detect the presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection.
because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or an adverse response. The term predictive test is often used to refer to the response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or predicting a response to therapy.

**Review of Evidence**

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Many studies have examined the association between the apolipoprotein E (APOE) epsilon 4 allele and AD. The Rotterdam and Framingham studies are examples of large observational studies demonstrating the association. The Rotterdam Study was a prospective cohort study in the city of Rotterdam, the Netherlands, with main objectives of investigating risk factors of cardiovascular, neurologic, ophthalmologic, and endocrine diseases in the elderly. In a sample of 6852 participants, carriers of a single ε4 allele had a relative risk of developing AD approximately double that of ε3/ε3 carriers. Carriers of the two, ε4 alleles had a relative risk of developing dementia approximately 8 times that of ε3/ε3 carriers. The Framingham Heart Study was a longitudinal cohort study initiated in 1948 in Framingham, Massachusetts, to identify common risk factors for cardiovascular disease. In 1030 participants, the relative risk for developing AD was 3.7 (95% confidence interval [CI], 1.9 to 7.5) for carriers of a single ε4 allele and 30.1 (95% CI, 10.7 to 84.4) for carriers with two ε4 alleles compared with those without a ε4 allele. The association between the APOE epsilon 4 allele and AD is significant; however, APOE genotyping does not have high specificity or sensitivity and is of little value in the predictive testing of asymptomatic individuals.

Associations between late-onset AD and more than 20 non-APOE genes have been suggested. Examples of large studies and meta-analyses on these non-APOE genes are discussed below. Naj et al (2014) published a genome-wide association study of multiple genetic loci in late-onset AD. Genetic data from 9162 white participants with AD, from the Alzheimer Disease Genetics Consortium, were assessed for variants at 10 loci significantly associated with risk of late-onset AD. The analysis confirmed the association between APOE and early-onset and found significant associations for the CRI, BINI, and PICALM genes. APOE contributed 3.7% of the variation in age of onset, and the other 9 loci combined contributed 2.2% of the variation. Each additional copy of the APOE epsilon 4 allele reduced the age of onset by 2.45 years.

Lambert et al (2013) published a large meta-analysis of a genome-wide association study of susceptibility loci for late-onset AD in 17,008 AD cases and 37,154 controls of European ancestry. Nineteen loci had genome-wide significance in addition to the APOE locus. The researchers confirmed several genes already reported to be associated with AD (ABCA7, BIN1, CD33, CLU, CRI, CD2AP, EPHA1, MS4A6A-MS4A4E, PICALM). New loci located included HLA-DRB5- HLA-DRBI, PTK2B, SORL1, and SLC24A4-RIN3.

Jonsson et al (2013) evaluated 3550 subjects with AD and found a genome-wide association for only 1 marker, the T allele of rs75932628 (excluding the APOE locus and the APPP11 A673T variant). The frequency of rs75932628 (triggering receptor expressed on myeloid cells 2 [TREM2]) was then tested in a general population of 110,050 Icelanders of all ages and found to confer a risk of developing AD of 0.63% (odds ratio [OR], 2.26; 95% CI, 1.71 to 2.98; p=1.13 x10⁻⁸). In the control population of 8,888 patients 85 years of age or older without a diagnosis of AD, the TREM2 frequency was 0.46% (OR, 2.92; 95% CI, 2.09 to 4.09; p=3.42 x10⁻¹⁰). In 1236 cognitively intact controls age 85 or older, the frequency of TREM2 decreased to 0.31% (OR, 4.66; 95% CI, 2.38 to 9.14; p=7.39 x10⁻⁶). The decrease in...
TREM2 frequency in cognitively intact elderly patients supports findings associating TREM2 with increasing risk of AD. Guerriero et al (2013) also found a strong association between the TREM2 R47H variant and AD (p=.001).\(^5\) Using 3 imputed data sets of a genome-wide association study, the meta-analysis found a significant association between the variant and AD (p=.002). The authors further reported direct genotyping of R47H in 1994 AD patients and 4062 controls, which detected a highly significant association between the variant and AD (OR, 5.05; 95% CI, 2.77 to 9.16; p=9.0 x10\(^{-9}\)). The effects of APOE and ancestry on AD risk in diverse populations continue to be elucidated.\(^16\)

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

There are no RCTs comparing outcomes of asymptomatic adults at risk for developing late-onset AD managed with and without genetic testing for AD.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study as reported by Chao et al (2008) was designed to examine the consequences of AD risk assessment by APOE genotype.\(^17\) Of 289 eligible participants, 162 were randomized (mean age, 52.8 years; 73% female) to risk assessment based on APOE testing plus family history (n=111) or family history alone (n=51). During a 1-year follow-up, those undergoing APOE testing with a high-risk genotype were more likely than low-risk or untested individuals to take more vitamins (40% vs. 24% and 30%), change diet (20% vs. 11% and 7%), or change exercise behaviors (8% vs. 4% and 5%), all respectively. There is insufficient evidence to conclude that these short-term behavioral changes would alter clinical outcomes. Green et al (2009) examined anxiety, depression, and test-related distress at 6 weeks, 6 months, and 1 year in the 162 participants randomized in REVEAL.\(^18\) However, there were no significant differences between the group that received the results of APOE testing and the group that did not, in changes in anxiety or depression overall, or the subgroup of participants with the APOE epsilon 4 allele. However, the ε4 negative participants had significantly lower test-related distress than ε4 positive participants (p=.01).

Christensen et al (2016) examined disclosing associations between APOE genotype and AD risk alone versus AD and coronary artery disease (CAD) risk in an equivalence trial from the REVEAL group.\(^19\) Two hundred ninety participants were randomized to AD risk disclosure alone or AD plus CAD risk disclosure. The 257 participants who received their genetic information were included in the analyses. Mean anxiety, depression, and test-related distress scores were below cutoffs for mood disorders at all time points in both disclosure groups and were similar to baseline levels. At the 12-month follow-up, both anxiety (measured by the Beck Anxiety Index) and depression (measured by the Center for Epidemiologic Studies Depression Scale) fell within the equivalence margin indicating no difference between disclosure groups. Among participants with a ε4 allele, distress (measured by Impact of Event Scale) was lower at 12 months in AD plus CAD group than in the AD-only group (difference, -4.8; 95% CI, -8.6 to -1.0; p=.031). AD plus CAD participants also reported more health behavior changes than AD-alone participants, regardless of APOE genotype.
There is no evidence that early intervention for asymptomatic disease-associated variant carriers can delay or mitigate future diseases. There are many actions patients can take following knowledge of a disease-associated variant. Changes in lifestyle factors (e.g., diet, exercise) and/or incorporation of “brain training” exercises can be made, but there is no evidence that these interventions impact clinical disease.

Section Summary: Genetic Testing for Late-Onset Alzheimer Disease
The APOE epsilon 4 allele is strongly associated with the incidence of and age at onset of AD; many other genes have shown statistical associations with AD incidence and onset, thus demonstrating some degree of clinical validity. However, the clinical sensitivity and specificity of the APOE epsilon 4 allele is poor, and there is a lack of evidence on the clinical sensitivity and specificity of other genes. It is unclear how changes in the management of asymptomatic patients with these genes would improve outcomes. The REVEAL studies found short-term changes in behaviors following disclosure of APOE genetic testing results in high-risk adults with little increase in anxiety or depression overall, although with a possible increase in distress among ε4 allele carriers. It is unclear whether these changes in behaviors would improve clinical outcomes or whether there are long-term effects on psychological outcomes among ε4 carriers. Therefore, the clinical utility has not been demonstrated for these tests.

Genetic Testing for Early-Onset Alzheimer Disease With and Without a Known Familial Variant Clinical Context and Test Purpose
The purpose of genetic testing in patients who are asymptomatic and at risk for developing early-onset AD is to inform management decisions such as initiation of AD therapy and to inform reproductive decision making. Asymptomatic patients at risk for early-onset AD are not generally treated with medical therapy.

The question addressed in this evidence review is: Does genetic testing improve health outcomes in individuals who are asymptomatic, at risk for developing early-onset AD, and have a known or unknown familial variant?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults who are asymptomatic and at risk for developing early-onset AD due to family history of early-onset AD, specifically those with autosomal dominant AD.

Interventions
Adults with a family history of early-onset AD caused by a known pathogenic amyloid-beta precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) variant would undergo targeted testing for the specific familial variant. In adults with a family history consistent with autosomal dominant AD but for whom the familial variant is unknown, genetic testing can be performed on the 3 genes (APP, PSEN1, PSEN2) individually or collectively. Multiple variants in these genes can cause early-onset AD, so sequencing the entire coding regions is necessary to comprehensively assess risk when the familial variant is unknown.

Comparators
The following practice is currently being used: targeted familial variant testing for those with a known familial variant and genetic testing for those without a known familial variant.

Outcomes
The general outcomes of interest are a change in disease status, health status measures, quality of life, and changes in reproductive decision making.
The potential beneficial outcome of primary interest would be change in reproductive decision making. Changes in management in asymptomatic patients at risk of AD might be initiated with the intent to prevent or slow the progression of cognitive decline leading to changes in disease status. Improvement in health status measures is also important.

Potential harmful outcomes are those resulting from a true- or a false-positive test result. Patients might suffer from psychological harm or anxiety after receiving positive test results.

Outcomes of reproductive decision making are relevant during child-bearing years for asymptomatic adults at risk.

### Study Selection Criteria

For the evaluation of clinical validity of genetic testing for AD, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard (describe the reference standard)
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Diagnostic tests detect the presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or an adverse response. The term predictive test is often used to refer to the response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or predicting a response to therapy.

### Review of Evidence

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

In the scenario of targeted testing of individuals with a known familial pathogenic variant, due to nearly complete penetrance of pathogenic variants, an identified carrier will almost certainly develop the disease unless dying at an age preceding disease onset. Therefore, clinical validity is nearly certain.

In the scenario of genetic testing of individuals with a family history consistent with autosomal dominant early-onset AD but in whom a pathogenic variant has not been found, the testing yield is less certain. Genetic testing for \( PSEN1 \) is estimated to detect disease-causing variants in 30% to 60% of individuals with familial early-onset AD,\textsuperscript{21,22} although estimates vary. A number of variants scattered throughout the \( PSEN1 \) gene have been reported, requiring sequencing of the entire gene when the first affected member of a family with an autosomal dominant pattern of AD inheritance is tested. Variants in \( APP \) and \( PSEN2 \) genes account for another 10% to 20% of cases.

Genetic yields may vary by population. Giau et al (2019) reported on 200 patients with clinically diagnosed early-onset AD from Thailand, Malaysia, the Philippines, and Korea who were genetically screened between 2009 and 2018.\textsuperscript{23} Thirty-two (16%) patients carried pathogenic \( APP (8/32 [25%]), PSEN1 (19/32 [59%]), \text{or PSEN2 (5/32 [16%])} \) variants. However, this analysis included possible and probable pathogenic variants in addition to those classified as definite. Overall, approximately
84% (p=.01) of autosomal dominant pedigrees in the tested Asian population were genetically unexplained.

Clinical and phenotypic expressivity is variable, ie, the presence of PSEN1, PSEN2, or APP variants is not useful in predicting the age of onset (although the age of onset is usually similar in affected family members), severity, type of symptoms, or rate of progression in asymptomatic individuals. A study by Cochran et al (2019) confirmed a high diagnostic yield in early-onset or atypical dementia. Fifty percent (16/32) of patients tested harbored 1 or more genetic variants capable of explaining symptoms, including variants in APP. Nine of 32 patients (28%) had a variant defined as pathogenic or likely pathogenic whereas 6 had 1 or more variants with moderate penetrance. The authors noted this supports a potential oligogenic model for early-onset dementia.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no RCTs comparing outcomes of asymptomatic adults at risk for developing early-onset AD managed with and without genetic testing for AD.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The potential clinical utility of testing is the early identification of asymptomatic patients who are at risk for developing early-onset AD. Genetic testing will in most cases lead to better risk stratification, distinguishing patients who will develop the disease from those who will not. If the early identification of patients at risk leads to interventions to delay or mitigate clinical disease, then the clinical utility would be established. Identification of asymptomatic, young adult carriers could impact reproductive planning. And clinical utility may be demonstrated if testing leads to informed reproductive planning that improves outcomes. Alternatively, the clinical utility could be demonstrated if knowledge of variant status leads to beneficial changes in psychological outcomes.

A systematic review, reported by Rahman et al (2012), which assessed the psychological and behavioral impact of genetic testing for AD, found few studies on the impact of testing for early-onset familial AD. The existing studies generally have small sample sizes and retrospective designs, and the research was conducted in different countries, which may limit the generalizability of the findings.

There is no evidence that early intervention for asymptomatic pathogenic variant carriers can delay or mitigate future diseases. There are many actions patients may take following knowledge of a pathogenic variant: changes in lifestyle factors (e.g., diet, exercise) and incorporation of “brain training” exercises; but there is no evidence that these interventions impact clinical disease. When a known pathogenic variant is identified in a prospective parent, with reasonable certainty, the disease will develop and there is a 50% risk of an affected offspring. For purposes of informing family planning, when a pathogenic variant is detected in a prospective parent, the prospective parent can choose to refrain from having children or choose medically assisted reproduction during which preimplantation testing would allow a choice to avoid an affected offspring. Identification of a
pathogenic variant by genetic testing is more accurate than the alternative of obtaining a family history alone. Therefore, testing in the reproductive setting can improve health outcomes.

**Section Summary: Genetic Testing for Early-Onset Alzheimer Disease**

The clinical validity for autosomal dominant, early-onset AD will be nearly certain when a pathogenic variant has previously been identified in a family pedigree or the variant database.

For those from families with early-onset, familial AD, when a pathogenic familial variant is known or when the family pedigree is consistent with autosomal dominant AD but the affected family members have not been tested to determine the familial variant, testing a prospective parent when performed in conjunction with genetic counseling provides more accurate information to guide reproductive planning than family history alone. Therefore, the clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. It is not clear how a change in the management of asymptomatic patients with these genes would improve outcomes. Outside of the reproductive setting when used for prognosis or prediction, there is insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants.

**Genetic Testing for Management of Amyloid-Beta Targeting Therapy**

**Clinical Context and Test Purpose**

The purpose of genetic testing in patients with mild cognitive impairment or mild dementia associated with AD who are considering or are currently being treated with an FDA-approved amyloid-beta targeting therapy is to inform management decisions such as initiation, discontinuation, or continuation of therapy.

The question addressed in this evidence review is: Does genetic testing improve health outcomes in individuals who are considering or currently being treated with an FDA-approved amyloid-beta targeting therapy?

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with mild cognitive impairment or mild dementia associated with AD who are being considered for or are currently being treated with an FDA-approved amyloid-beta targeting therapy (e.g., aducanumab).

**Interventions**

The intervention of interest is genetic testing, used in addition to clinical diagnosis or assessment of cognitive and functional response to therapy, to inform amyloid-beta targeting therapy management decisions (e.g., initiation, discontinuation, or continuation of therapy).

**Comparators**

The following practice is currently being used: standard clinical management without genetic testing.

**Outcomes**

The general outcomes of interest are symptoms, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related morbidity and mortality.

The outcome of primary interest would be changes in treatment decision-making that result in beneficial improvements in health status measures, such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory-10 (NPI-10), and other AD-specific assessment scales. Follow-up at 2 to 5 years is of interest to monitor health outcomes.
Study Selection Criteria
For the evaluation of clinical validity of genetic testing for AD, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard (describe the reference standard)
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Diagnostic tests detect the presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or an adverse response. The term predictive test is often used to refer to the response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or predicting a response to therapy.

Review of Evidence
Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Exploratory analyses of pooled safety data from 2 phase 3 trials of the FDA-approved amyloid-beta targeting therapy aducanumab indicate that APOE ε4 carrier status is associated with a higher incidence of amyloid-related imaging abnormalities (ARIA). Specifically, the incidence of ARIA-edema was 43% versus 20%, in APOE ε4 carriers and non-carriers receiving a 10 mg/kg dose of aducanumab, respectively. The overall incidence of any ARIA ranged from 36-41% in the treatment group compared to 10.3% in the placebo group. The clinical effects of ARIA range from asymptomatic to severe. Although the majority of patients were asymptomatic or had symptoms such as headache, confusion, or dizziness that resolved with temporary stoppage of the drug, 6.2% of participants receiving the high dose of aducanumab discontinued the drug due to ARIA compared to 0.6% in the placebo arm.

The majority of ARIA-edema radiographic events occurred early in treatment (within the first 8 doses), although ARIA can occur at any time. Among patients treated with a planned dose of aducanumab 10 mg/kg who had ARIA-edema, the maximum radiographic severity was mild in 30%, moderate in 58%, and severe in 13% of patients (refer to prescribing label for classification of severity of ARIA). Resolution occurred in 68% of ARIA-edema patients by 12 weeks, 91% by 20 weeks, and 98% overall after detection. Ten percent of all patients who received aducanumab 10 mg/kg had more than 1 episode of ARIA-edema. Radiographic severity and symptomatic status were similar for APOE ε4 carriers and non-carriers.

Aducanumab dosing management decisions in the trials were based on clinical symptom severity and ARIA severity on MRI. After radiographic resolution of ARIA-edema or stabilization of ARIA-hemorrhage and resolution of symptoms (if present), participants could resume dosing at the same dose and titration schedule.

Limited follow-up data are available for the safety analysis because the phase 3 trials were stopped prematurely for futility.

See evidence review 5.01.38 for additional aducanumab study details.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no RCTs comparing health outcomes of patients who are considering or currently undergoing treatment with aducanumab with and without genetic testing for APOE carrier status.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The potential clinical utility of testing is the identification of patients who are at increased risk of ARIA related to treatment with aducanumab. Clinical utility may be demonstrated if testing leads to changes in treatment management decisions (e.g., initiation, discontinuation, or continuation of therapy) that leads to beneficial health outcomes. However, treatment with aducanumab has not demonstrated a net benefit in health outcomes (see evidence review 5.01.38). Therefore, a chain of evidence cannot be established.

Section Summary: Genetic Testing for Management of Amyloid-Beta Targeting Therapy
Two randomized clinical trials of aducanumab for the treatment of mild cognitive impairment or mild dementia associated with Alzheimer disease demonstrated an increased incidence of ARIA following treatment with the amyloid-beta targeting therapy. Specifically, the incidence of ARIA-edema was 22% higher in APOE ε4 carriers compared to non-carriers, requiring dose modifications in 45% of carriers exposed to a full 10 mg/kg dose. Carriers and non-carriers had similar rates of radiographic severity and symptomatic status. Resolution occurred in 98% of ARIA-edema patients overall, and most cases were observed within the first 8 doses. While the APOE status of patients may identify those at higher risk for ARIA, the clinical benefit of aducanumab has not been established.

Summary of Evidence
For individuals who are asymptomatic and at risk for developing late-onset AD who receive genetic testing, the evidence includes studies on gene associations, test accuracy, and effects on health outcomes. Relevant outcomes are test accuracy and validity, change in disease status, health status measures, and quality of life. Many genes, including APOE, CRI, BIN1, PICALM, and TREM2, are associated with late-onset AD. However, the sensitivity and specificity of genetic testing for indicating which individuals will progress to AD is low, and numerous other factors can affect progression. Overall, genetic testing has not been shown to add value to the diagnosis of AD made clinically. The current lack of effective methods to prevent the onset of AD limits the clinical benefit for genetic testing. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic, at risk for developing early-onset, autosomal dominant AD, and have a known familial variant who receive targeted genetic testing, the evidence includes studies on gene associations and test accuracy. Relevant outcomes are test accuracy and validity, change in disease status, change in reproductive decision making, health status measures, and quality of life. Variants in the PSEN1 and PSEN2 and APP genes are known to cause early-onset AD in an autosomal dominant pattern with almost complete penetrance. The clinical validity for autosomal dominant early-onset AD will be nearly certain when a familial pathogenic variant has previously been identified. Outside the reproductive setting when used for prognosis or prediction, there is
insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants. Testing a prospective parent, when performed in conjunction with genetic counseling, provides more accurate information to guide reproductive planning than family history alone. Therefore, the clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic, at risk for developing early-onset, autosomal dominant AD, and have no known familial variant who receive genetic testing, the evidence includes studies on gene associations and test accuracy. Relevant outcomes are test accuracy and validity, change in disease status, change in reproductive decision making, health status measures, and quality of life. Variants in the PSEN1, PSEN2, and APP genes are known to cause early-onset AD in an autosomal dominant pattern with almost complete penetrance. The clinical validity for autosomal dominant early-onset AD will be reasonably certain when a variant found in the database of pathogenic PSEN1, PSEN2, and APP variants are identified. Outside the reproductive setting when used for prognosis or prediction, there is insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants. Testing a prospective parent, when performed in conjunction with genetic counseling, provides more accurate information to guide reproductive planning than family history alone. Therefore, the clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with a clinical diagnosis of mild cognitive impairment or mild dementia associated with AD who are considering initiation or discontinuation of an FDA-approved amyloid-beta targeting therapy who receive genetic testing, the evidence includes 2 randomized clinical trials. Relevant outcomes are test accuracy and validity, symptoms, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related morbidity and mortality. The incidence of ARIA following treatment with the amyloid-beta targeting therapy aducanumab was 23% higher for ARIA-edema in APOE ε4 carriers compared to non-carriers, requiring dose modifications in 45% of carriers exposed to a full 10 mg/kg dose. Carriers and non-carriers had similar rates of radiographic severity and symptomatic status. While the APOE status of patients may identify those at higher risk for ARIA, the clinical benefit of aducanumab has not been established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Medical Genetics and Genomics et al
The American College of Medical Genetics and Genomics (ACMG) has listed genetic testing for apolipoprotein E (APOE) alleles as 1 of 5 recommendations in the Choosing Wisely initiative. The recommendation is “Don’t order APOE genetic testing as a predictive test for Alzheimer disease.” The stated rationale is that APOE is a susceptibility gene for late-onset Alzheimer disease (AD), the most common cause of dementia: “The presence of an ε4 allele is neither necessary nor sufficient to cause AD. The relative risk conferred by the ε4 allele is confounded by the presence of other risk alleles,
gender, environment and possibly ethnicity, and the APOE genotyping for AD risk prediction has limited clinical utility and poor predictive value.”

In 2011, the ACMG, jointly with the National Society of Genetic Counselors issued the following joint practice guidelines:

- “Pediatric testing for AD should not occur. Prenatal testing for AD is not advised if the patient intends to continue a pregnancy with a mutation.
- Genetic testing for AD should only occur in the context of genetic counseling (in person or through video conference) and support by someone with expertise in this area.
  - Symptomatic patients: Genetic counseling for symptomatic patients should be performed in the presence of the individual's legal guardian or family member.
  - Asymptomatic patients: A protocol based on the International Huntington Association and World Federation of Neurology Research Group on Huntington's Chorea Guidelines is recommended.
- DTC [direct-to-consumer] APOE testing is not advised.
- A ≥3-generation family history should be obtained, with specific attention to the age of onset of any neurologic and/or psychiatric symptoms, type of dementia and method of diagnosis, current ages, or ages at death (especially unaffected relatives), and causes of death. Medical records should be used to confirm AD diagnosis when feasible. The history of additional relatives may prove useful, especially in small families or those with a preponderance of early death that may mask a history of dementia.
- A risk assessment should be performed by pedigree analysis to determine whether the family history is consistent with EOAD [early-onset AD] or LOAD [late-onset AD] and with autosomal dominant (with or without complete penetrance), familial, or sporadic inheritance.
- Patients should be informed that currently there are no proven pharmacologic or lifestyle choices that reduce the risk of developing AD or stop its progression.
- The following potential genetic contributions to AD should be reviewed:
  - The lifetime risk of AD in the general population is approximately 10-12% in a 75-80 year lifespan.
  - The effect(s) of ethnicity on risk is still unclear.
  - Although some genes are known, there are very likely others (susceptibility, deterministic, and protective) whose presence and effects are currently unknown.

For families in which an autosomal dominant AD gene mutation is a possibility:

- Discuss the risk of inheriting a mutation from a parent affected with autosomal dominant AD is 50%. In the absence of identifying a mutation in apparent autosomal dominant families, risk to offspring could be as high as 50% but may be less.
- Testing for genes associated with early-onset autosomal dominant AD should be offered in the following situations:
  - A symptomatic individual with EOAD in the setting of a family history of dementia or the setting of an unknown family history (e.g., adoption).
  - Autosomal dominant family history of dementia with one or more cases of EOAD.
  - A relative with a mutation consistent with EOAD (currently presenilin [PSEN]1/2 or amyloid-beta precursor protein [APP]).

The Alzheimer Disease & Frontotemporal Dementia Mutation Database should be consulted before disclosure of genetic test results, and specific genotypes should not be used to predict the phenotype in diagnostic or predictive testing.

- Discuss the likelihood of identifying a mutation in PSEN1, PSEN2, or APP, noting that current experience indicates that this likelihood decreases with lower proportions of affected family members and/or older ages of onset.
- Ideally, an affected family member should be tested first. If no affected family member is available for testing and an asymptomatic individual remains interested in testing despite counseling about the low likelihood of an informative result (a positive result for a pathogenic mutation), he/she should be counseled according to the recommended protocol. If the
affected relative, or their next of kin, is uninterested in pursuing testing, the option of DNA banking should be discussed.”

In 2019, ACMG reaffirmed its position in the original document. However, an addendum was issued clarifying 2 points:

1. Use of the phrase “pathogenic variant” should be adopted rather than the word “mutation” in discussing pathogenic variants related to autosomal dominant EOAD.
2. Because the original document no longer meets the criteria for an evidence-based practice guideline by either the ACMG or National Society of Genetic Counselors, both societies have since reclassified it as a Practice Resource.

American Academy of Neurology
In 2001 (reaffirmed 2004), the American Academy of Neurology made the following guideline recommendations for the diagnosis of dementia:

1. Routine use of APOE genotyping in patients with suspected AD is not recommended at this time.
2. There are no other genetic markers recommended for routine use in the diagnosis of AD.

National Institute for Health and Care Excellence
In 2018, the National Institute for Health and Care Excellence (NICE) published guidelines on the assessment, management, and support of people living with dementia. The guidelines state that APOE genotyping should not be used to diagnose Alzheimer’s disease.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00064870</td>
<td>National Cell Repository for Alzheimer’s Disease (NCRAD)</td>
<td>3000</td>
<td>Jul 2026 (recruiting)</td>
</tr>
<tr>
<td>NCT01998841</td>
<td>A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer’s Disease</td>
<td>252</td>
<td>Dec 2022 (ongoing)</td>
</tr>
<tr>
<td>NCT01760005*</td>
<td>A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer’s Disease (DIAN-TU)</td>
<td>490</td>
<td>Jul 2022 (recruiting)</td>
</tr>
<tr>
<td>NCT03876314</td>
<td>The Effect of Physical Activity on Cognition Relative to APOE Genotype (PAAD-2)</td>
<td>240</td>
<td>Mar 2023 (recruiting)</td>
</tr>
<tr>
<td>NCT03634007*</td>
<td>A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer’s Disease</td>
<td>15</td>
<td>Sep 2024 (recruiting)</td>
</tr>
</tbody>
</table>
### Table

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT05400330</td>
<td>Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease (LEADLTFU)</td>
<td>15</td>
<td>Dec 2027</td>
</tr>
<tr>
<td>NCT04241068</td>
<td>Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)</td>
<td>1696</td>
<td>Feb 2025 (ongoing)</td>
</tr>
<tr>
<td>NCT04770220</td>
<td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype</td>
<td>300</td>
<td>Jul 2024 (recruiting)</td>
</tr>
<tr>
<td>NCT00869817</td>
<td>Dominantly Inherited Alzheimer Network (DIAN)</td>
<td>700</td>
<td>Jul 2024 (recruiting)</td>
</tr>
<tr>
<td>NCT04680013</td>
<td>Genetic Studies in Familial Dementia</td>
<td>20,000</td>
<td>Nov 2025</td>
</tr>
<tr>
<td>NCT0365732</td>
<td>A Multi-center Longitudinal Cohort Study of Familial Alzheimer's Disease in China (CFAN)</td>
<td>40,000</td>
<td>Jan 2038 (recruiting)</td>
</tr>
<tr>
<td>NCT02564692</td>
<td>Alzheimer's Prevention Registry GeneMatch Program</td>
<td>500,000</td>
<td>Dec 2030</td>
</tr>
<tr>
<td>Unpublished</td>
<td>Tau PET Longitudinal Substudy Associated With: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-randomized, Placebo-treated Non-carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease</td>
<td>150</td>
<td>Apr 2022</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
° Denotes industry-sponsored or cosponsored trial.

### References


**Documentation for Clinical Review**

Please provide the following documentation:

- History and physical and/or consultation notes including:
  - Diagnosis
  - Family history
  - Genetic counseling notes
- How test result will impact clinical decision making including but not limited to how it might affect reproductive decision making
- Reason for performing test
- Signs/symptoms/test results related to reason for genetic testing
- Lab results documenting both partners carrier status or genetic disorder
- Provider order for genetic test
- Name and description of genetic test
- CPT codes billed for the particular genetic test

Post Service (in addition to the above, please include the following):

- Laboratory report(s)

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.
### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/02/2010</td>
<td>New policy</td>
</tr>
<tr>
<td></td>
<td>Policies combined:</td>
</tr>
<tr>
<td></td>
<td>Apolipoprotein E Epsilon (apoE) 4 Allele and Alzheimers Disease: Role for Genetic Testing for Diagnosis and Risk Management</td>
</tr>
<tr>
<td></td>
<td>Cerebrospinal Fluid and Urinary Assays of Neuronal (Neural) Thread Protein in the Diagnosis of Alzheimers Dementia</td>
</tr>
<tr>
<td>04/19/2012</td>
<td>Added documentation required for clinical review</td>
</tr>
<tr>
<td>02/22/2013</td>
<td>Coding Update.</td>
</tr>
<tr>
<td>02/27/2015</td>
<td>Policy title change from Alzheimer's Disease - Genetic and Biochemical Testing</td>
</tr>
<tr>
<td></td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>09/01/2016</td>
<td>Policy title change from Genetic Testing for Familial Alzheimer's Disease</td>
</tr>
<tr>
<td></td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>11/01/2017</td>
<td>Policy revision with position change</td>
</tr>
<tr>
<td>06/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>07/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>07/01/2020</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>01/01/2021</td>
<td>Coding Update.</td>
</tr>
<tr>
<td>06/01/2021</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>12/01/2021</td>
<td>Policy statement, guidelines and literature updated.</td>
</tr>
<tr>
<td>03/01/2022</td>
<td>Coding update.</td>
</tr>
<tr>
<td>03/01/2022</td>
<td>Coding update.</td>
</tr>
<tr>
<td>12/01/2022</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>03/01/2023</td>
<td>Coding update.</td>
</tr>
<tr>
<td>12/01/2023</td>
<td>Annual review. No change to policy statement. Policy guidelines updated</td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished
primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*
### POLICY STATEMENT

(No changes)

<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
</table>
| **Genetic Testing for Alzheimer Disease 2.04.13**

**Policy Statement:**

I. Targeted genetic testing for a known familial variant in the presenilin (PSEN1, PSEN2) genes or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease (AD) may be considered **medically necessary** in an asymptomatic or minimally symptomatic individual to determine future risk of disease when the individual has a close relative (i.e., first- or second-degree relative) with a known familial variant associated with autosomal dominant early-onset Alzheimer disease (see Policy Guidelines).

II. Genetic testing for variants in presenilin (PSEN1, PSEN2) genes or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease may be considered **medically necessary** in an asymptomatic or minimally symptomatic individual to determine future risk of disease when the individual has a family history of dementia consistent with autosomal dominant Alzheimer disease for whom the genetic status of the affected family members is unavailable.

III. Genetic testing for the risk assessment of Alzheimer disease in asymptomatic individuals is considered **investigational** in all other situations. Genetic testing includes but is not limited to, testing for the apolipoprotein E (APOE) epsilon 4 (ε4) allele or triggering receptor expressed on myeloid cells 2 (TREM2).

IV. Genetic testing to guide initiation or management of a U.S. Food and Drug Administration-approved amyloid-beta targeting therapy (e.g., aducanumab) is considered **investigational**. Genetic testing includes but is not limited to, testing for the APOE epsilon 4 allele.